Phytochemical drug candidates for the modulation of peroxisome proliferator-activated receptor γ in inflammatory bowel diseases
- PMID: 32009281
- DOI: 10.1002/ptr.6625
Phytochemical drug candidates for the modulation of peroxisome proliferator-activated receptor γ in inflammatory bowel diseases
Abstract
Plant-based compounds or phytochemicals such as alkaloids, glycosides, flavonoids, volatile oils, tannins, resins, and polyphenols have been used extensively in traditional medicine for centuries and more recently in Western alternative medicine. Extensive evidence suggests that consumption of dietary polyphenolic compounds lowers the risk of inflammatory diseases. The anti-inflammatory properties of several phytochemicals are mediated through ligand-inducible peroxisome proliferator-activated receptors (PPARs), particularly the PPARγ transcription factor. Inflammatory bowel disease (IBD) is represented by ulcerative colitis, which occurs in the mucosa of the colon and rectum, and Crohn's disease (CD) that can involve any segment of gastrointestinal tract. Because of the lack of cost-effective pharmaceutical treatment options, many IBD patients seek and use alternative and unconventional therapies to alleviate their symptoms. PPARγ plays a role in the inhibition of inflammatory cytokine expression and activation of anti-inflammatory immune cells. The phytochemicals reported here are ligands that activate PPARγ, which in turn modulates inflammatory responses. PPARγ is highly expressed in the gut making it a potential therapeutic target for IBDs. This review summarizes the effects of the currently published phytochemicals that modulate the PPARγ pathway and reduce or eliminate colonic inflammation.
Keywords: PPARγ; colitis; inflammatory bowel disease; phytochemicals.
© 2020 John Wiley & Sons, Ltd.
Similar articles
-
Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?Clin Exp Immunol. 2016 Mar;183(3):358-68. doi: 10.1111/cei.12732. Epub 2015 Nov 26. Clin Exp Immunol. 2016. PMID: 26462859 Free PMC article.
-
Molecular Docking Identifies 1,8-Cineole (Eucalyptol) as A Novel PPARγ Agonist That Alleviates Colon Inflammation.Int J Mol Sci. 2023 Mar 24;24(7):6160. doi: 10.3390/ijms24076160. Int J Mol Sci. 2023. PMID: 37047133 Free PMC article.
-
Phytochemicals and their potential usefulness in inflammatory bowel disease.Phytother Res. 2015 Mar;29(3):339-50. doi: 10.1002/ptr.5271. Epub 2015 Jan 9. Phytother Res. 2015. PMID: 25572840 Review.
-
PPARgamma as a new therapeutic target in inflammatory bowel diseases.Gut. 2006 Sep;55(9):1341-9. doi: 10.1136/gut.2006.093484. Gut. 2006. PMID: 16905700 Free PMC article. Review.
-
Evidence that peroxisome proliferator-activated receptor γ suppresses squamous carcinogenesis through anti-inflammatory signaling and regulation of the immune response.Mol Carcinog. 2019 Sep;58(9):1589-1601. doi: 10.1002/mc.23041. Epub 2019 May 20. Mol Carcinog. 2019. PMID: 31111568 Review.
Cited by
-
Thymoquinone, a Dietary Bioactive Compound, Exerts Anti-Inflammatory Effects in Colitis by Stimulating Expression of the Colonic Epithelial PPAR-γ Transcription Factor.Nutrients. 2021 Apr 17;13(4):1343. doi: 10.3390/nu13041343. Nutrients. 2021. PMID: 33920708 Free PMC article.
-
Viburnum opulus L. Juice Phenolics Inhibit Mouse 3T3-L1 Cells Adipogenesis and Pancreatic Lipase Activity.Nutrients. 2020 Jul 6;12(7):2003. doi: 10.3390/nu12072003. Nutrients. 2020. PMID: 32640537 Free PMC article.
-
Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus.Pharmaceuticals (Basel). 2022 Dec 11;15(12):1538. doi: 10.3390/ph15121538. Pharmaceuticals (Basel). 2022. PMID: 36558989 Free PMC article.
-
PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases.Int J Mol Sci. 2021 Jan 15;22(2):805. doi: 10.3390/ijms22020805. Int J Mol Sci. 2021. PMID: 33467433 Free PMC article. Review.
-
The "root" causes behind the anti-inflammatory actions of ginger compounds in immune cells.Front Immunol. 2024 Jun 28;15:1400956. doi: 10.3389/fimmu.2024.1400956. eCollection 2024. Front Immunol. 2024. PMID: 39007134 Free PMC article. Review.
References
REFERENCES
-
- Adachi, M., Kurotani, R., Morimura, K., Shah, Y., Sanford, M., Madison, B. B., … Gonzalez, F. J. (2006). Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut, 55(8), 1104-1113. https://doi.org/10.1136/gut.2005.081745
-
- Agostini, M., Schoenmakers, E., Beig, J., Fairall, L., Szatmari, I., Rajanayagam, O., … Savage, D. B. (2018). A pharmacogenetic approach to the treatment of patients with PPARG mutations. Diabetes, 67(6), 1086-1092. https://doi.org/10.2337/db17-1236
-
- Arafa, H. M., Hemeida, R. A., El-Bahrawy, A. I., & Hamada, F. M. (2009). Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food and Chemical Toxicology, 47(6), 1311-1317. https://doi.org/10.1016/j.fct.2009.03.003
-
- Atri, C., Guerfali, F. Z., & Laouini, D. (2018). Role of human macrophage polarization in inflammation during infectious diseases. International Journal of Molecular Sciences, 19(6), 1801-1815. https://doi.org/10.3390/ijms19061801
-
- Avila-Roman, J., Talero, E., Alcaide, A., Reyes Cde, L., Zubia, E., Garcia-Maurino, S., & Motilva, V. (2014). Preventive effect of the microalga Chlamydomonas debaryana on the acute phase of experimental colitis in rats. The British Journal of Nutrition, 112(7), 1055-1064. https://doi.org/10.1017/S0007114514001895
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources